Kevesy

Levetiracetam, the active ingredient in Kevesy, is an antiepileptic presented as an intravenous solution for intravenous use. It is used to treat partial‑onset, generalized and myoclonic seizures in patients with epilepsy.

GNH USA supplies Kevesy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levetiracetam is an antiepileptic medication used to control various seizure types.

- Partial‑onset seizures: reduces frequency and severity of focal seizures. - Generalized seizures: helps prevent tonic‑clonic episodes. - Myoclonic seizures: decreases sudden muscle jerks associated with epilepsy.

Levetiracetam may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Fatigue: feeling unusually tired or weak. - Headache: mild to moderate pain in the head region. - Somnolence: increased sleepiness during the day. - Nausea: upset stomach or urge to vomit. - Irritability: mood changes or increased agitation.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Stevens‑Johnson syndrome: rare but serious skin disorder. - Blood dyscrasias: abnormal blood cell counts. - Suicidal thoughts: emergence of depressive or suicidal ideation. - Severe skin rash: extensive blistering or peeling. - Respiratory depression: markedly reduced breathing effort.

Before initiating therapy with Kevesy, consider the following safety measures.

- Renal impairment: adjust dose in patients with reduced kidney function. - Hepatic impairment: monitor liver function and consider dose modification. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Concomitant CNS depressants: observe for enhanced sedation or respiratory effects. - Mood changes: monitor for depression or suicidal ideation. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Levetiracetam has a low interaction profile, but certain drugs may alter its effectiveness or increase risk.

Major Interactions (Avoid): - Carbamazepine: enzyme induction may lower levetiracetam levels. - Phenytoin: may reduce levetiracetam plasma concentration. - Phenobarbital: can decrease levetiracetam exposure. - Rifampin: strong inducer that may diminish therapeutic effect. - Topiramate: may increase risk of CNS side effects.

Moderate Interactions (Monitor Closely): - Benzodiazepines: additive sedation and respiratory depression. - Alcohol: enhanced central nervous system depression. - Other antiepileptics: monitor seizure control and side‑effect profile. - Antidepressants: watch for mood alterations. - Antipsychotics: potential increase in dizziness or somnolence.